TGA Warns Against Unapproved Peptide Products Over Safety Risks

TGA Warns Against Unapproved Peptide Products Over Safety Risks

14 Apr 2026

The Therapeutic Goods Administration (TGA) has warned healthcare practitioners and suppliers about the growing use of unapproved peptide products in Australia.

It says these products are being widely promoted on social media and online platforms with claims including weight loss, muscle growth, anti-ageing, and improved physical and cognitive performance.

However, the regulator says these substances have not been assessed for safety, quality, or effectiveness, creating significant public health risks.

Some peptide-based medicines, such as semaglutide and tirzepatide, are approved and properly regulated in Australia. But the TGA says many online products fall outside this category and are not listed on the Australian Register of Therapeutic Goods.

Health experts warn that unapproved products may contain incorrect doses, contaminants, or unknown ingredients, which can pose serious risks to users.

The TGA is also reminding practitioners that prescribing, compounding, or supplying these products must follow strict regulatory and professional standards, including those set by the Australian Health Practitioner Regulation Agency (Ahpra).

Authorities say they are actively monitoring the issue and taking action against illegal advertising and supply of unapproved medicines, including those promoted through social media influencers and fitness groups.

https://www1.racgp.org.au/

Source: Therapeutic Goods Administration (TGA)
 

Categories

Popular Posts

Recent Posts

Tags